Form 4: Teva Pharmaceutical Industries: EVP, CFO Eliyahu Sharon Kalif Reports Share Transactions

Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the vesting of restricted share units and acquisition of ordinary shares.

Summary

• On March 5, 2025, Eliyahu Sharon Kalif, the EVP and CFO of Teva Pharmaceutical Industries, reported transactions involving ordinary shares and restricted share units.
• 21,390 restricted share units vested, resulting in the acquisition of 21,390 ordinary shares.
• Following these transactions, Kalif directly owns 459,063 ordinary shares.
• Additionally, 79,664 restricted share units were granted on March 5, 2025, vesting in equal installments from March 5, 2026, to March 5, 2029.

Sentiment

Score: 5

Explanation: This is a neutral report on executive share transactions, with no inherent positive or negative implications for the company's performance.

Future Outlook

The reporting person will continue to receive vesting restricted share units in the coming years.

Industry Context

This filing is a routine disclosure of executive compensation in the form of equity, common in the pharmaceutical industry to align management interests with shareholder value.

Comparison to Industry Standards

• Equity compensation is a standard practice among pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson to incentivize executives.
• The vesting schedules and types of equity grants (restricted share units) are comparable to those offered by peer companies.
• The specific amounts and terms of the grants would need to be benchmarked against similar roles and company performance to determine if they are in line with industry standards.

Stakeholder Impact

• The vesting of restricted share units may have a minor dilutive effect on existing shareholders.
• The transactions reflect the compensation structure for key executives, which is of interest to shareholders.

Key Dates